Komal Jhaveri
Medical Oncology · New York, NYNPI 1871822288
Payments from drug & device makers
Across 975 payments — averaging $22,896 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6.3M
- Genentech, Inc.$5.6M
- AstraZeneca$2.6M
- Puma Biotechnology, Inc.$2.6M
- Pfizer$2M
- Novartis$1.9M
- plus $1.3M from 24 others
Across 91 payments — averaging $3688.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$239K
- Eli Lilly$48K
- F. Hoffmann-la Roche AG$29K
- Novartis$19K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 149 | $6,287,639 |
| Genentech, Inc. | 292 | $5,593,719 |
| AstraZeneca | 120 | $2,611,234 |
| Puma Biotechnology, Inc. | 26 | $2,594,381 |
| Pfizer | 122 | $1,991,820 |
| Novartis | 27 | $1,903,058 |
| Gilead | 76 | $599,229 |
| Blueprint Medicines Corporation | 19 | $274,185 |
| Immunomedics, Inc. | 5 | $84,034 |
| E.r. Squibb & Sons, L.L.C. | 2 | $71,954 |
| Sanofi US Services Inc. | 11 | $61,751 |
| Astrazeneca UK Limited | 40 | $53,615 |
| Daiichi Sankyo Company LTD | 9 | $38,401 |
| Hoffmann-la Roche Limited | 7 | $35,278 |
| Daiichi Sankyo Inc. | 9 | $23,809 |
| F. Hoffmann-la Roche AG | 11 | $19,264 |
| Roche Products Limited | 6 | $14,041 |
| Lilly USA, LLC | 5 | $12,800 |
| Stemline Therapeutics Inc. | 14 | $12,374 |
| Merck | 7 | $9,423 |
| Genentech USA, Inc. | 5 | $8,698 |
| Sanofi | 3 | $8,053 |
| Eisai Inc. | 2 | $5,450 |
| Seagen Inc. | 2 | $3,025 |
| Novartis Pharma AG | 1 | $2,700 |
| Beone Medicines USA, Inc. | 1 | $1,600 |
| Taiho Oncology, Inc. | 1 | $938 |
| Bayer | 1 | $700 |
| GE HealthCare | 1 | $31 |
| AbbVie | 1 | $25 |
How this compares
$22,323,228 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
- Rona YaegerNew York$17.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.